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ABSTRACT
Immunological Markers Detected in Peri-Implant Crevicular Fluid Detected by MSD
Electromagnetic ELISA Assay – A Pilot Study of Dental Implant Patients
Paul Canallatos, D.D.S

Objectives: The purpose of this pilot study is to determine if, in healthy states, there are
significant differences in cytokine activity in peri-implant crevicular fluid (PICF) between
implants restored in an edentulous patient (ES) and implants restored in a dentate patient (DS).
Methods: In this pilot study, peri-implant crevicular fluid was obtained from sixteen total
patients –eight dentate patients restored with fixed restoration implants and eight edentulous
patients restored with implant retained overdenture. Paper points were used to obtained the periimplant GCF and then were processed using the MSD Meso Quickplex SQ 120 machine. A 96well Proinflammatory Panel 1 (human) Kit V-Plex, coated with capture-antibodies to IFN-γ, IL1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and, TNF-α, and a 96-well Cytokine Panel 1
(Human) kit V-Plex, coated with capture-antibodies to GM-CSF, IL-1α, IL-5, IL-7, IL-12/23
p40, IL-15, IL-16, IL-17A, TNF-β, and, VEGF, were used and prepared exactly according to
manufacturer specifications without deviation.
Results: There were significant differences between PICF of ES group and DS groups.
Significant differences, at the p<0.05 interval, were noted in IL-1α, IL-12/23p40, IL-10, IL-15,
and VEGF.
Conclusions: Statistically significant differences were detected between certain cytokines in
PICF of dentate subjects compared to edentulous subjects. There was no correlation noted in the
numerical concentrations of cytokines between the statistically significant differences. There is
a tendency towards higher levels of cytokines/inflammatory markers in PICF of implants in
dentate patients compared to edentulous patients
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CHAPTER I: INTRODUCTION
Background
Modern endosteal dental implants have been used to restore missing teeth
effectively in North America since the 1980’s. They have provided patients with a higher
quality of life whether they are being used to retain removable dental prostheses or for
fixed dental prostheses1. Their benefit to the field of prosthetic dentistry for the treatment
of missing teeth has allowed for new treatment modalities to be explored. When planned
from a restoratively- driven aspect, utilizing an appropriate surgical protocol, and proper
restoration with adequate occlusion, implant success rates have been shown to be
remarkably high, allowing the clinician to suggest dental implants as an excellent option
when treatment planning with patients1.
As successful as implants have been, they have not been immune to complications
and failures. Implant failures have been noted in the literature and the practices of those
clinicians that choose to deal with implant therapy for patients1. Risk factors, whether
local or systemic, have been reported to give clinicians an educated gauge as to the
success a patient will have, prior to placement1. Implant failure has been shown to be
multifactorial, at times, leaving the clinician unable to identify the cause of the
progression from healthy to hopeless dental implants1. It would be highly beneficial if
there were measurable indicators to help determine the health of an implant and whether
or not it may be on its way to a diseased state.
Much like natural dentition, implants have a sulcus holding a fluid that contains
multiple bacterial organisms and pro-inflammatory proteins. This peri-implant crevicular
fluid, much like that of gingival crevicular fluid surrounding natural dentition, has a
1

multitude of different elements within it that reflect the status of periodontal health that
supports the implant1. This peri-implant crevicular fluid holds measurable indicators that
could help clinicians determine whether or not an implant is healthy or displaying a shift
in microflora/inflammatory markers that could be weakening the dental implant1.
Inflammatory markers have not been studied to the extent of microbiota, thus looking
farther into this aspect of oral health could bring us one step closer to understanding the
etiology between peri-mucositis and peri-implantitis. Prior to understanding a diseased
state, it is imperative to fully comprehend a healthy, stable environment. Nonetheless, a
healthy environment for an implant restored in a dentate patient may be different than
that of an implant placed in an edentulous patient. If these factors are measureable in the
peri-implant crevicular fluid, one must question whether or not there are differences
between implants in edentulous patients and implants in dentate patients.
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Statement of the Problem
1. In clinically healthy implants in healthy individuals, are there significant
differences between the cytokines in the peri-implant crevicular fluid of
implants in a dentate patient versus an edentulous patient restored with
implants?
Significance of the Problem
Implants have become the standard of care for partially or fully edentulous
patients2. One of the problems with implants, despite being the standard of care, is that
patients may have lost their dentition due to prior inadequate home care2,3. Peri-implant
inflammation and failures is a problem clinicians face. Although bacterial plaque is
considered the primary etiological factor of peri-implant diseases4-6, other factors play a
significant role in these diseases, such as the intensity of the inflammatory response to
bacterial products, like lipopolysaccharides and endotoxin4. These products generate
cytokines’ release by host inflammatory cells, thus leading to bone loss around implants4.
Cytokines have been shown to have higher expression in diseased states4,7,8. This higher
expression of proinflammatory cytokines can affect the T helper cell response, generating
different patterns of cytokines expression7. Leading to an immune cell response,
predominantly mediated by cytotoxic T cells, macrophages, neutrophils, and natural
killer cells4, which ultimately leads to destruction of local tissues.
Researchers have found that even in conditions of minimal bacterial accumulation
or clinical health, inflammatory cytokines may still be produced in substantial amounts911

. These biomarkers are indicators of a biological state and can help to distinguish

between normal and pathological processes12. Currently, probing depths, clinical
attachment level, radiographs, and bleeding on probing are used for diagnosis12,13.
3

Biomarkers have advantages because of their non-invasive nature of being collected13.
There is a wide range of percentages and causes of peri-implantitis. Researchers and
clinicians are always looking for additional measures to aid in proper diagnosis and early
detection of disease state by the measurement of levels of enzymes and biomarkers12.
Currently, there are no definitive concentrations of cytokines that would deem a site to be
diseased or healthy. Correlations have been established as to which markers are more
prevalent in certain clinical situations14. Before a definitive concentration for diagnostic
purposes could be obtained, it is important to have a baseline measurement of the clinical
situation without evidence of disease. Two clinical situations that have not been
compared to date are the constituents of peri-implant crevicular fluid around implants in
dentate versus edentulous patients.
The purpose of this study is to determine if, in healthy states, significant
differences are found in cytokine activity in peri-implant crevicular fluid between
implants restored in an edentulous patient and implants restored in a dentate patient.
Hypothesis
There will be significant differences in proinflammatory markers and cytokine
markers that are found in the peri-implant crevicular fluid of healthy implants when
comparing implants in edentulous patients and implants in dentate patients.
Null Hypothesis
There will not be significant differences in proinflammatory markers and cytokine
markers that are found in the peri-implant crevicular fluid of healthy implants when
comparing implants in edentulous patients and implants in dentate patients.

4
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Definition of Terms
Cytokine: A large group of proteins made by cells that are capable of regulating a
wide variety of cellular functions15.
Dentate: having teeth16.
Edentulous: without teeth, lacking teeth16.
ELISA: Acronym for enzyme-linked immunoadsorbent assay wherein an
enzyme-antibody complex binds to an agent thought to be present in a sample.
Typically, an enzyme-activated dye is used to detect the presence of bound
immunoglobulin-enzyme complex. The amount of color is proportional to the
concentration of bound antibody/suspect agent present in the test sample15.
Gingival Crevicular Fluid (GCF): Tissue fluid that seeps through the crevicular
and junctional epithelium. It is increased in the presence of inflammation15.
Inflammation: A localized protective response elicited by proximate microbes
and/or tissue injury, which serves to destroy, dilute, or wall off both the injurious
agent and the injured tissue. A cellular and vascular reaction of tissues to injury15.
Interleukin: A family of potent proteins that serves as a link between inducer and
effector cells during immune and inflammatory responses; involved in the
recruitment of immune and inflammatory precursor cells. Some interleukins have
been implicated in the pathogenesis of periodontal disease15.
Microbiota: The microscopic living organisms of a region15.
Peri-Implantitis: a term used to describe inflammation around a dental implant,
which is an irreversible condition that involves the breakdown of soft tissue and
supporting bone.16.
6

Periodontitis: Inflammation of the supporting tissues of the teeth. Usually a
progressively destructive change leading to loss of bone and periodontal ligament.
An extension of inflammation from gingiva into the adjacent bone and ligament15.
Peri-Implant Crevicular Fluid (PICF): fluid surrounding an implant (see GCF)

7

Assumptions
1. It is assumed the subjects understand the consent and the procedure that
was performed.
2. It is assumed that all paper points and laboratory equipment were sterile.
3. It is assumed that there was no salivary contamination.
4. It is assumed the instrument used in this study is valid and reliable.
5. It is assumed the patients reported their medical history accurately and
there were no systemic conditions present.

Limitations
1. The subjects of the study were limited to patients at West Virginia University
School of Dentistry. Findings may not be representative of the larger, general
population.
2. There was a limited sample size.
Delimitations
1. Subjects were chosen from the West Virginia University Graduate
Prosthodontic clinic patient pool due to patients’ familiarity with the clinic.
2. The amount of patients was determined by the limitations of the MSD
Mesoscale plates that were available for researcher usage.
8

Chapter II: LITERATURE REVIEW
Peri-implant mucositis/Peri-implantitis
Peri-implant diseases are important to understand in order to prevent failures of
dental implants. Peri-implant diseases can present as either peri-implant mucositis or
peri-implantitis. Both of these diseases are characterized by an inflammatory reaction in
the tissues surrounding an implant14,17,18. Peri-implant mucositis has been described as
inflammation of the surrounding implant tissue with no involvement of osseous structure
or clinical attachment loss14. Peri-implantitis has been characterized by an inflammatory
process around an implant, which includes both soft tissue inflammation and progressive
loss of supporting bone beyond biological bone remodeling14,19. This disease can be
caused by an imbalance between the bacterial load and host defense20, which could affect
the mucosa, the bone, or both. In a review by Rosen et al in 2013, it was shown that
peri-implant mucositis could occur in subjects 31% to 59.6% of the time between a time
frame of 6.3 to 10.8 years, while peri-implantitis could occur in 16% to as much as,
47.1% of subjects between a time frame of 5.7 to 14 years after implant placement14.
These numbers indicate that there is variability in the prevalence of these conditions,
nonetheless, indicate that there is a problem that necessitates attention.
Detection of the disease will greatly influence the severity of its effects. The
clinical signs of peri-implant mucositis include bleeding on probing and possibly
suppuration14, while peri-implantitis includes all of the clinical signs of peri-implant
mucositis, in addition to bone loss. These clinical signs, if caught early enough, can aid
in treatment that can reverse or prevent further damage. Peri-implant mucositis, much
9

like gingivitis, is reversible when effectively treated14,21,22. Peri-implantitis, like
periodontitis, occurs primarily as a result of a bacterial load and subsequent host immune
response, leading to tissue breakdown14. There are inflammatory markers up- regulated
by the immune system in peri-implantitis and periodontitis, which include, but are not
limited to, IL-1, IL-6, IL-8, IL-12 and TNFα23,24. These markers signal local tissue
destruction and will be discussed in sections below in further detail.
In an effort to foresee any complications, risk factors should be taken into
consideration prior to commencement of implant therapy. Risk factors that have been
well documented include history of periodontitis, diabetes, genetic traits, poor oral
hygiene, smoking, alcohol consumption, absence of keratinized mucosa and implant
surface, residual cement, occlusal overload14,20. History of periodontitis is significant
when considering risk factors because it shows the effect adjacent teeth and their
conditions could have on adjacent implants and their peri-implant tissue health. It has
been shown that implant bone loss has been different in patients with a history of
periodontitis and those who have not had this disease25-27. This indicates a strong
influence of surrounding dentition on the implants’ overall health. Karoussis et al26
performed a study which concluded that patients with a history of chronic periodontitis
may have greater long-term marginal bone loss and incidence of peri-implantitis
compared with periodontally healthy subjects. Diagnosing peri-implant mucositis before
bone loss has occurred to be crucial to the prognosis of the implant before it can progress
to peri-implantitis.
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Cytokines
Cytokines is the general term for a large group of molecules involved in signaling
between cells during immune responses28. All cytokines are proteins or glycoproteins
acting as molecular messengers that communicate information between cells. They
induce their effects by binding to high-affinity receptors on target cell membranes and
help recruit cells and vascularity to a local site29. They are categorized as interleukins,
growth factors, chemokines, and interferons10. Interferons (IFNs) are important in
limiting viral infections; for example, cells that have become infected by a virus produce
IFNα and IFNβ. IFNγ is another type, which is released by activated T Helper 1 (Th1)
cells and has been shown to be very active in periodontitis and local dental
inflammation28. Interleukins are produced mainly by T cells, though some are produced
by mononuclear phagocytes, and cause other cells to divide and differentiate.
Chemokines are a large group of chemotactic cytokines that direct the movement of
leukocytes around the body. Finally, growth factors are very important in directing the
division and differentiation of bone marrow stem cells and precursors of blood leukocytes
into the necessary cell to handle the threat30. Among these, there is a small subset of
cytokines that are important in mediating inflammation and cytotoxic reactions, these
include the tumor necrosis factors, TNFα and TNFβ28.
T cells are vital to the function of the immune system and are divided into T
Helper 1 (Th1) and T Helper 2 (Th2) cells. Th1 cells release cytokines that promote
interactions with mononuclear phagocytes, Th2 cells release a different set of cytokines
to activate B cells28. These cytokines aid in the interaction between these cells,
instructing them to either recruit more cells or to perform an action. Each cytokine does

11

not solely have one function, but are part of an integrated web that allows the human
immune system to function30.
Cytokines that were chosen in this study are regularly mediators of inflammation
and infection. The cytokine plates that were used contain several antibodies raised
against a specific protein applied to the tray. Each cytokine that was tested in this study
will be introduced in the following paragraphs. Interleukin -1 (IL-1) is divided into two
forms: IL-α and IL-β. Interleukin-1βeta is the predominant form of IL-1, which is
primarily produced by macrophages. Interleukin -1 alpha have very similar structure to
that of IL-1β, but are encoded by separate genes31. Just like IL-1β, they act on endothelial
cells to increase attachment of neutrophils and monocytes, thus recruiting these cells to
the site of inflammation. IL-α is produced primarily by macrophages. The cellular origin
of IL-1α is speculative, according to Masada et al31, and ten times less likely to be found
than IL-1β.
Interleukin-4 (IL-4) is produced by plasma cells, and they promote TH2 and
activate B-cells and antibody production. Antibodies that are produced by IL-4 can be
protective by helping elimination of infection32, Interleukin 6 is a multifunctional protein
that stimulates immunoglobulin secretion by human B-lympthocytes and activates Tcells33, It has also been shown to play a major role in terminal differentiation of Blymphocytes to plasma cells, which are predominantly inflammatory33. Interleukin-8 (IL8) is a classical inflammatory cytokine that is produced by macrophages and epithelial
cells, which stimulates neutrophil chemotaxis during bacterial exposure11,34,35.
Interleukin-10 (IL-10) is produced by TH2 cells and inhibits cytokine production of TH1
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cells, which has an inhibitory effect on macrophage-monocytes, thus giving it an antiinflammatory effect36,37.
Although present in the literature, IL-2, IL-5, IL-7, IL-12, IL-13, IL-15, IL-16,
and IL-17 are not widely discussed from a dental aspect, but they play a powerful role in
inflammation. Interleukin -2 (IL-2) is produced by activated T cells and they are
involved in T cell proliferation and differentiation, B Cell proliferation, and cytolytic
activity28. Interleukin-5 (IL-5) is made by T lymphocytes, and cause B lymphocytes to
increase in proliferation and eosinophils to be activated and proliferate. Interleukin (IL7) , produced by the stromal cells, is a major factor in supporting pre-B cell growth,
alongside IL-328,30. Interleukin-12 (IL-12) has multiple variations that are named after the
receptors that they bind to. IL-12p30 and IL-12/23 p40 are made by monocytes and B
cells. These both induce IFN -γ production by T and Natural Killer (NK) cells and
inhibit Ig E production. Interleukin-13 (IL-13) is produced by activated T and B cells.
IL-13 causes B cell growth and differentiation factor and stimulates chemotaxis.
Interleukin-15 (IL-15) is produced by mononuclear cells and NK cells. They stimulate
activated B, T and NK cells and chemoattractant. Interleukin-16 (IL-16) is produced by
T cells and eosinophil and has chemotaxis capabilities for CD4 cells. Interleukin-17 (IL17) is produced by Th17 cells and is a regulator of inflammation in various aspects28.
Tumor necrosis factor (TNF) is present in two forms: TNF-alpha (TNF-α) and
TNF-beta(TNF-β). TNF-α is made by macrophages and lymphocytes. It can activate
macrophages, granulocytes and cytotoxic cells, stimulate angiogensis, and induce cell
adhesion. TNF-β are made by mast cells, platelets, and fibroblasts and are important in
wound repair, cell growth regulation, tissue remodeling and immunosuppression30.
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Vacular endothelial growth factor (VEGF) plays a role in diseased and healthy
sites, suggesting that its presence maintains periodontal health, but it is also present in
chronic inflammatory periodontal disease38. VEGF induces other functional alterations in
endothelial cells38,39, causing vascular permeability, and is crucial in neovascularization38.
Due to its role in angiogenesis, it is a prominent feature of both inflammation and
healing. VEGF has been shown to be induced by IL-1 and TNF-α.38
Interferon gamma (IFN-γ) is made by T cells and NK cells. It can increase
phagocytosis of PMNs and macrophages by activating them, inhibiting progression of
infection. They also induce endothelial cell/lymphocyte adhesion40. Granulocyte
macrophage colony stimulating factor (GM-CSF) comes from T cells, macrophages,
endothelial cell, and B cells, and they inhibit apoptosis, proliferation, differentation and
activation of granulocytes and macrophages28.
These cytokines are displayed throughout the body, in varying quantities
depending on the threat or pathogen that is presently disrupting the normal homeostasis.
Our focus will be drawn to the cytokines that have had the most influence in the oral
cavity.
Cytokines in Oral Environment
There is a continuous balance that exists between host immune response and
potential subgingival pathogens around teeth. This continuous balance shines light on the
fact that there will always be inflammatory markers that are present around teeth, even if
they are clinically healthy9,41. These inflammatory markers, or cytokines, act as signals
and feedback to the body to either activate an immune response or keep the status quo.
Cytokines have a dose-response curve that shows that although these markers might be
14

present, they don’t always elicit a negative response unless the quantity surpasses a
threshold41. Once the threshold is met, it activates the immune system.. To date, no
numerical concentration of cytokines has been determined to which a.response will be
clinically seen.
Innate response cytokines are necessary for the recruitment of polymorphonuclear
leukocytes (PMNs), specifically by IL-8, and subsequent stimulation of monocytes,
macrophages, and PMNs (IL-1β and TNF-α). Vascular changes are also related to these
cytokines (IL-1β and TNF-α), allowing for the transmigration of inflammatory cells
within the connective tissues and through the sulcus10,42. Low levels of PMNs in
clinically healthy gingival tissues are common findings around healthy teeth (and
implants), thus low levels of IL-8 should be observed since it is produced by PMNs43.
It is critical to understand the different markers to appreciate what the clinical
situation may be if they are elevated. There is a fine line between healthy and preinflammatory states. It has been shown that levels of IL-1β and IL-8 in GCF can be
elevated before clinical signs of inflammation appear44. Zhang et al45 proved this in their
gingivitis model that showed that after three days of plaque accumulation, there were
elevated levels of IL-1β before clinical signs of inflammation appeared45. Increased levels
of IL-1 have been reported in periodontitis and gingivitis. IL-1 enables recruitment of
cells towards infection sites, promotes bone resorption, and stimulates prostaglandin
(PGE2) release by monocytes and fibroblasts, and release of metalloproteinases that
degrade extracellular matrix proteins36,46,47. ΙL-1β is thoroughly studied in the literature,
alongside with TNF-α. IL-1β and TNF-α appear to play major roles in mediating the
inflammatory response in the pathogenesis of many chronic inflammatory diseases9,48,49.
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Due to its role in chronic inflammatory disease, IL-1β is found at elevated levels in GCF
in periodontitis and peri-implant inflammation. IL-1β is produced primarily by
monocytes, or by other nucleated cells, in response to injury and has elevated levels when
associated with periodontitis9,36,46,47. Nonetheless, IL-1α and IL-1β are the principal
inflammation induced cytokines stimulating bone resorption in periodontitis11,50,51.
Tsai et al40 showed that IL-4 was much higher after scaling and root planing was
performed, which supports the finding that it may play a role in regulating the degree of
local inflammation in periodontal disease. IL-6 has a major role in terminal
differentiation of B-lymphocytes to plasma cells giving it proinflammatory effects that
are responsible for collagen resorption of gingival tissues9,41. It has been shown to be
involved in established and advanced periodontal disease33,52. Sakai et al11 found that IL8 is significantly higher in diseased states yet still present at significant levels in healthy
states. IL-8 is considered to be a mediator of granulocyte accumulation36,53-55.
TNF-α is similar to IL-8 and is also found in sites affected by periodontitis.
These two act synergistically to initiate the cascade of inflammatory mediators9. Other
cytokines that are involved in this process, such as IL-12, appear to induce the secretion
of Interferon (IFN-γ) from activated T and Natural Killer (NK) cells56, and IL-8 acts as a
potent chemoattractant for neutrophils57.
Periodontal disease is a process by which there is cellular destruction of the
supporting structures of the teeth. Major tissue destruction in established periodontitis
lesions results from recruitment of host cells via activation of different cell types36.
Proinflammatory cytokines are synthesized in response to periodontopathogenic bacteria

16

and their byproducts, hence inducing an inflammatory response in the
periodontium36,58,59.
The oral environment has the ability to stimulate and depress the immune system,
depending on the status of the threat it is trying to combat. IL-6 and IL-10 can inhibit the
production of cytokines, lessening the effect of destruction36,60. IL-6 may act as an antiinflammatory by inhibiting the production of IL-1β and TNF-α in conjunction with IL-10.
Phagocytosis, or the engulfment and destruction of cells or material61, is necessary to
remove unwanted foreign substance or excess cells that were created to combat whatever
threat was present. IL-12 is responsible for controlling phagocytosis10.
As evident in the literature, cytokines can give an adequate snapshot into the
health of an implant or tooth in the oral cavity. Acquisition of these materials have been
studied whether through saliva, blood, or the sulcular fluids. Blood is a possible medium
through which cytokines can be tested, but it is more systemic and will not give the local
picture that is directly adjacent to the object in question. Saliva also has many other
factors that can offer a general idea of the oral cavity, but it cannot be used to study
localized areas. Sulcular or crevicular fluid has been a widely studied sample due to its
ease of acquisition and the components that are specific to the substance in which it
surrounds, in addition to the fact that this fluid is closest to the structure in question.
Gingival Crevicular Fluid
It has been known that gingival crevicular fluid, or sulcular fluid, has defense
mechanisms since the work of Waerhaug and Brill and Krasse in the 1950s62. Studying
sulcular fluid has been very popular in the periodontal world due to the non-invasive
methods of acquisition and its snapshot into the health of the structure it surrounds.
17

Dorland’s medical dictionary61 defines the fluid as the interstitial fluid and plasma that
seeps into the gingival sulcus. Brill and Krasse showed the similarities in composition
between this fluid and the bloodstream63. Sulcular fluid, in small quantities, can hold
substances that can build up or destroy the structure that it surrounds. Challacombe
stated that gingival crevicular fluid could has a volume of 0.43 to 1.56µl could be found
in the interproximal spaces between molar teeth64. In this minute amount of fluid, there
are cellular elements, electrolytes, organic compounds, and enzymes. Due to its
components, this fluid has been studied to potentially develop patient-specific diagnostic
tests for periodontal disease65.

Peri-Implant Crevicular Fluid
Peri-implant crevicular fluid (PCIF) is remarkably similar to gingival crevicular
fluid9. The same gradient exists between the blood stream and the sulcus that exists
between the gingival tissue and the implant surface or abutment9. Due to its similarities
with gingival crevicular fluid, focus should be drawn to the differences between these
two substances. When analyzing the substituents in the PICF, cytokine production was
at higher levels in contrast to natural dentition10. It has been suggested that implants act
as a foreign object, which results in these higher cytokine secretions 9. For many years,
titanium has been considered as the most biologically compatible material for the
fabrication of implants of different kinds, but Nowzari et al10 found higher concentrations
of cytokines around implants, which raised questions for other authors to answer as to
why these concentrations were higher10,66. Cadosch et al66 found that because implants
are not entirely inert, a slow liberation of titanium molecules is possible, and in
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conjunction with bacterial accumulation, this would give the explanation as to why
implants may have higher cytokine levels than natural dentition has. 10,66

In addition to

the titanium molecules, Perala and colleagues indicated that dental implant surfaces may
lead to an activation of human mononuclear cells (Lymphocytes, NK cells, T Cells) for
the secretion of IL-1β and TNF-α 9,67. These two cytokines can lead to bone resorption
and collagen degradation9.
Due to the foreign nature of their composition to the human body, dental implants
are at a disadvantage, except susceptibility to caries, when compared to natural dentition.
In addition to this setback, implants are also battling against similar bacterial
accumulation as teeth are. Papaioannou et al68 have studied the similarities between
periodontal pathogens that cause periodontitis and the periodontal pathogens that cause
peri-implantitis. They reported that patients with high numbers of periodontal pathogens
around teeth are at an increased risk of cross-infection with bacteria from periodontal
sites to implants 23,68. It has been widely studied that periodontitis and peri-implantitis are
closely linked, thus showing a strong influence of the dental GCF composition on PICF
23,69-72

.
Due to this close relationship, de Waal et al73 performed a review evaluating peri-

implant microflora between fully and partially edentulous patients. A review of a study
by Socransky et al74 revealed that the “hard tissue” surfaces influence the composition of
the biofilm, and the gingival crevicular fluid is essential for the colonization of these
bacteria 73. This was supported in a study that showed a significant reduction of
periodontal pathogens (Aggregatibacter actinomycetemcomitans and Porphyromonas
gingivalis) after full mouth extraction 75, but had higher detection frequencies after
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implant placement and with an increasing detection rate the longer the implants were in
function 76. In fully edentulous patients, the bacteria in biofilms originate primarily from
intraoral soft tissues while partially edentulous patients have bacteria that originates from
the subgingival area of neighboring teeth 73. Great similarities in the composition of the
subgingival microflora at implants and teeth within the same mouth have been found 73,7779

. It has been shown that partially edentulous patients harbor more potentially

pathogenic peri-implant microflora compared to fully edentulous patients.73.
As stated earlier, cytokines have a direct correlation to the types of bacteria that
are present. The components of the immune system, especially cytokines, that are
designed to protect the body from pathogenic bacteria, can attack the periodontium.
Evidence indicates that inflammatory cytokines, released by the host’s monocytes and
macrophages in response to bacterial products such as lipopolysaccharide (LPS) and
endotoxin, are responsible for breakdown of periodontium in periodontitis 2,80,81. Thus,
studies have been aimed at determining which cytokines are collected in high levels
during peri-implant inflammation. Teles et al44 reported that higher levels of interleukins
(IL-1β and IL-8) in “clinically healthy” sites suggest that inflammatory mechanisms take
place within the gingival tissues, in both GCF and PICF, before they can be clinically
detected.
Another important cytokine that plays an important role in inflammatory response
is vascular endothelial growth factor (VEGF). Higher levels of VEGF have been found
around inflamed peri-implant tissues with deep peri-implant pockets compared with
healthy implant tissues 82. Thus, Nogueira-Filho et al82 concluded that low levels of
VEGF may indicate clinical stability in peri-implant tissues.
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Peri-implant inflammation may be affected by local factors other than bacterial
biofilms, such as implant system and location of the micro-gap10,82.
Concerning amounts of PICF, it was noted that PICF fluid volume is increased
when probing depths have increased and in cases where inflammation is present 65. Along
with the amount of fluid, quantities of cytokines in PICF have attempted to be measured
to make a standard for diagnosis. At the current time, PICF as a single measure cannot
account for the complexity of the whole system; therefore, a number of objective
measures and clinical judgment remain important to establish the early diagnosis of a
failing implant83. This study is a pilot study used to determine if baseline measurements
could be obtained for implants in dentate subjects and implants in edentulous subjects. It
is hopeful that this study will warrant future studies aiming to investigate baseline
measurements of different healthy clinical situations in order to obtain a range of
numerical values that a diagnostician could use to compare to ailing implants.
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Chapter III: MATERIALS AND METHODS
Participant Acquisition
Participants were obtained from the patients of West Virginia University Graduate
Prosthodontics clinic. Utilizing and Institutionally Reviewed Protocol
(IRB#1506713764), a thorough review of active and recall patients, within the
department, was performed. A total of sixteen patients were recruited – eight dentate
patients with implants (DS) and eight edentulous patients with implants (ES). A total of
one implant per patient was sampled. Due to ease of isolation, if multiple implants were
present, the most anterior implant’s PICF was sampled due to ease of isolation. All
patients included were in good systemic health with no signs of clinical peri-implantitis
or peri-implant mucositis. Exclusion criteria for this study included anyone presenting
with local periodontal or systemic disease. Local disease was characterized by bleeding
on probing, clinical attachment loss, more than four millimeters of periodontal probing
depth, and radiographic bone loss that was not stable in the last year.

Systemic diseases

excluded were poorly controlled diabetes, current smokers, metabolic bone disease, and
immunocompromised or autoimmune disorders.

Patients were also excluded if they had

any antibiotic or steroidal treatments within the last three months. All patients had
implants in function for at least 6 months to no variability with adaptation to a new
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restoration. Once patients were obtained, they were assigned a subject number, 1-8 for
edentulous patients with implants (ES) and 9-16 for dentate patients with implants (DS).
A master list with the patient’s name and assigned number was kept in the locked office
of the principal investigators office within the Graduate Prosthodontics clinic.
Anonymity was maintained throughout the entirety of the experiment and documentation
of the experiment. Patients were properly informed of the clinical implications of the
experiment, including risks and benefits of the procedures. Each patient was given a
written consent, which was reviewed aloud, and then ample time was given to review the
information before consenting to treatment. Once documentation was complete, the
experiment commenced.
Sample Acquisition
Once patients were consented, PICF sampling commenced. Two different
experiments were run at the same time in order to measure a wide variety of cytokine
markers. The MSD Meso Quickplex SQ 120 machine electrochemical ELISA machine
(MSD, Gaithersburg, MD) was used for processing of samples. Due to availability, two
different plates were used to allow for maximum amount of cytokines to be tested. For
each plate, ten inflammatory markers were tested. Following manufacturer’s
recommended protocols, cytokines were divided into two different plates according to
cross-reactivity and dilution factors that allow them to be optimally placed together. The
two plates were named by MSD as Proinflammatory Panel 1 (human) Kit V-Plex, which
had antibodies to IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and, TNFα, and Cytokine Panel 1 (Human) kit V-Plex, which had antibodies to GM-CSF, IL-1α,
IL-5, IL-7, IL-12/23 p40, IL-15, IL-16, IL-17A, TNF-β, and, VEGF.
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Properly labeled 1.8ml vials with 1.0ml of TE Buffer, provided by MSD
Mesoscale, were used. Each patient had two sealed vials with TE Buffer labeled either P
(Proinflammatory) or Cy (Cytokines) followed by their corresponding pre-assigned
subject number.

Using cotton roll isolation and 2x2 gauze, the site was dried of any

extra-sulcular fluids. Six medium absorbent paper points, (BencoDental, Wilkes-Barre,
PA) were used for each implant, collecting samples from mesiofacial, midfacial,
distofacial, distolingual, midlingual, and mesiolingual. To ensure adequate sample, no
more than two paper points were inserted into the peri-implant sulcus at a time. They
remained in the sulcus for 30 seconds, and then they were placed into the labeled vial. In
all 16 subjects, the six absorbent paper points that were used to run the proinflammatory
markers plates were gathered first, followed by the acquisition of the samples for the
cytokine markers. A minimum of 5 minutes passed between proinflammatory and
cytokine sample gathering to ensure adequate replenishment of peri-implant crevicular
fluid. Once all samples were gathered, they were immediately placed into a portable
freezer and brought to the main laboratory to be stored in a labeled container and placed
in a -20 degree Celsius freezer.
Processing Samples
The samples were processed on the MSD Meso Quickplex SQ 120 machine
(MSD, Gaithersburg, MD). The samples were thawed and prepared using manufacturer’s
protocol, under sterile conditions and utilizing solutions provided by the MSD company
(MSD, Gaithersburg, MD). These solutions include calibrator stock, control stock,
detection antibody stock, wash buffer, and read buffer T. A 96-well Proinflammatory
Panel 1 (human) Kit V-Plex, coated with capture-antibodies to IFN-γ, IL-1β, IL-2, IL-4,
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IL-6, IL-8, IL-10, IL-12p70, IL-13, and, TNF-α , and a 96-well Cytokine Panel 1
(Human) kit V-Plex, coated with capture-antibodies to GM-CSF, IL-1α, IL-5, IL-7, IL12/23 p40, IL-15, IL-16, IL-17A, TNF-β, and, VEGF, were used and prepared according
to manufacturer specifications. Detection antibodies were coupled with SULFOTAG
labels which emit a light when electrochemically stimulated via carbon-coated electrodes
at the bottom of each well (MSD, Gaithersburg, MD). To ensure accuracy, all samples
were duplicated on the plate, in different wells, to ensure accuracy. The mean of these
concentrations were used for the raw data. Data was analyzed by MSD Mesoscale
Discovery Workbench 4.0.

Statistical Analysis
Calculated concentration values, displayed in picograms per milliliters, were
obtained from the sixteen samples. These calculated concentration values were obtained
for each of the proinflammatory and cytokine markers. A mean concentration value was
calculated for each sample. The mean value of the calculated concentration was
calculated and obtained by MSD Mesoscale Discovery Workbench Software.
For each proinflammatory and cytokine marker, the calculated concentration
mean was obtained for the two groups, compared using a One-Way ANOVA. JMP® Pro
Version 12 (Cary, NC) was used to statistically evaluate data comparing the dentate and
edentulous groups. Significant value between the groups was set at p<0.05.
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Chapter IV
RESULTS
A total of sixteen patients were evaluated for this study. Eight subjects were in
the completely-edentulous restored with implants group (ES) and eight subjects were in
the dentate restored with single implant crown group (DS). Each subject had enough
sample taken to ensure adequate amounts to be run on two different plates. Each sample
was duplicated within the cytokine and proinflammatory plate to determine the accuracy
of the processing of each sample. The mean values were calculated for each sample. For
the purposes of this research study, calculated concentration mean was used to compare
the differences between edentulous and dental implant groups.
Proinflammatory Results
A total of ten proinflammatory markers, including IFN-γ, IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12p70, IL-13, and, TNF-α, were tested in all sixteen subjects. Data for
edentulous subjects is listed in Table 1 and data for dentate subjects is listed in Table 2.
If the quantity of calculated concentration mean was too low to be detected, that sample
was excluded from the measurements for that particular marker. The concentrations that
were detected by MSD machine are in red font. These are considered to be in the
detection range which is determined by the calibrators. The calibrators are determined by
the National Institute for Biological Stands and Control, as well as World Health
Organization. The cytokines that fail to register are weighted heavily on fewer results
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leading to a less reliable conclusion. The total amount of observations and the mean of
the concentrations are listed in Table 3. The amount of detected concentrations for
edentulous subjects is listed under ES and the amount of detected concentrations for
dentate subjects is listed under DS. The F ratio and P values are listed, including
statistically significant values highlighted in red (p<0.05). For all markers, there was an
overall higher level (pg/ml) of calculated concentration in DS than in ES subject groups,
with exception to IL-4 , which showed very similar values. The highest mean response
was for IL-8 being 94.77 pg/ml and the lowest response for IL-4 at 0.11 pg/ml. IL-10 was
significantly different between the DS group and the ES group with a p value of 0.044.
There is a tendency that shows difference between concentrations found in ES and DS
when concerning IL-13 and TNF-α, but these were not statistically significant. The data
for IL-10 in graph representation, shown in Figure 1, shows approximately half of the
samples below detection range and half of the samples within the detection range. The
detection range is predetermined by the software which includes the lower limit of
detection, which is is a calculated concenttration 2.5 standard deviations above the lowest
point on the calibration curve, and the upper limit of detection is the highest calibrator
point. The curve is a standard curve, which the software generates by using raw signals
from calibrators. The plots that are below the detection range show that there was not a
significant concentration when compared to the calibrators. All 16 samples recorded a
value for IL-10.
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Table 1: Calculated Concentration Means of Proinflammatory Markers for Edentulous
Subjects (ES) (pg/ml)
ES 01
ES 02
ES 03
ES 04
ES 05
ES 06
ES 07
ES 08
Average
Max
Min

IFN-γ
0.228
0.409
0.689
0.093
0.428
0.369
0.689
0.093

IL-10
0.019
0.005
0.124
0.267
0.044
0.128
0.119
0.035
0.093
0.267
0.005

IL-12p70
0.040
0.036
0.020
0.026
0.043
0.045
0.015
0.032
0.045
0.015

IL-13
0.824
0.531
3.674
0.727
1.065
1.364
3.674
0.531

IL-1β
3.644
1.555
4.673
56.315
5.700
4.448
12.173
1.087
11.199
56.315
1.087

IL-2
0.029
0.079
0.060
0.056
0.079
0.029

IL-4
0.014
0.007
0.014
0.010
0.011
0.014
0.007

IL-6
0.190
0.328
1.171
0.145
0.173
0.426
0.123
0.185
0.343
1.171
0.123

IL-8
0.269
0.511
1.691
0.772
0.335
1.714
0.143
0.291
0.716
1.714
0.143

TNF-α
0.269
0.511
1.691
0.772
0.335
1.714
0.143
0.291
0.716
1.714
0.143

* Data in red indicates that the concentration was in detection range

Table 2: Calculated Concentration Means of Proinflammatory Markers for Dentate
Subjects (DS) (pg/ml)
DS 09
DS 10
DS 11
DS 12
DS 13
DS 14
DS 15
DS 16
Average
Max
Min

IFN-γ
3.602
0.882
0.461
0.976
0.646
4.007
0.194
1.538
4.007
0.194

IL-10
0.121
0.938
1.675
0.048
0.346
0.662
2.584
0.067
0.805
2.584
0.048

IL-12p70
0.021
0.086
0.037
0.051
0.012
0.071
0.060
0.027
0.046
0.086
0.012

IL-13
5.924
2.576
2.437
2.990
2.724
3.330
5.924
2.437

IL-1β
12.668
88.875
81.604
4.323
21.000
13.562
35.179
15.898
34.139
88.875
4.323

IL-2
0.219
0.128
0.121
0.080
0.134
0.044
0.121
0.219
0.044

IL-4
0.006
0.012
0.008
0.017
0.003
0.020
0.011
0.020
0.003

IL-6
0.578
1.578
0.503
0.116
0.937
0.160
1.529
0.772
1.578
0.116

* Data in red indicates that the concentration was in detection range
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IL-8 TNF-α
1.298 1.298
5.622 5.622
0.963 0.963
0.449 0.449
4.086 4.086
1.367 1.367
2.376 2.376
0.137 0.137
2.037 2.037
5.622 5.622
0.137 0.137

Table 3: ANOVA of Calculated Concentration Means of Proinflammatory Markers
MARKER ES DS Total Observations Mean of Response F Ratio
P VALUES
IFN-γ
5 7
12
1.051332
2.6453 0.134913359
IL-10
8 8
16
0.448905
4.8939 0.044078421 a
IL-12p70 7 8
15
0.039295
1.5555 0.234330213
IL-13
5 5
10
2.347231
5.0233 0.055316075
IL-1β
8 8
16
22.66913
2.9658 0.107051177
IL-2
3 6
9
0.099298
3.1539 0.119004092
IL-4
4 6
10
0.011114
0.0004 0.984327461
IL-6
8 7
15
0.542834
2.9572 0.10919505
IL-8
8 8
16
94.76917
2.2078 0.159486735
TNF-α
8 8
16
1.376372
3.4573 0.084116424
a
Represents significant differences at the P <0.05 interval (JMP/Pro
Ver12, SAS Inst. Inc., Cary, NC).
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Figure 1a. IL-10 Calculated Concentration Mean Plot (MSD Discovery Workbench
4.0)

Figure 1b. Statistical Plot for Calculated Concentration Mean of IL-10
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Cytokine Markers
A total of ten proinflammatory markers, including GM-CSF, IL-1α, IL-5, IL-7,
IL-12/23 p40, IL-15, IL-16, IL-17A, TNF-β, and, VEGF, were tested in all sixteen
subjects. Data for edentulous subjects is listed in Table 4 and data for dentate subjects is
listed in Table 5. Similarly to above, if the quantitiy was undetectable, that sample was
excluded from the measurements for that particular marker. The total amount of
observations are listed in Table 6, followed by the total amount of DS and ES samples
that were used for the analysis. For all markers, there was an overall higher level (pg/ml)
of calculated concentration in DS than in ES subject groups, with exception to GM-CSF ,
which showed similar values. The highest mean response was 329.09 pg/ml, by IL-1α,
and the lowest mean reading was 0.042pg/ml, by TNF-β. Out of the ten markers that
were tested, four of them showed a significant difference between DS and ES. The
markers that showed significant differences are IL-12/23 p40 (p=0.042), IL-15
(p=0.027), IL-1α (p=0.038), and VEGF (p=0.010).
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Table 4: Calculated Concentration Means of Cytokine Markers for Edentulous Subjects
(ES) (pg/ml)
ES 01
ES 02
ES 03
ES 04
ES 05
ES 06
ES 07
ES 08
Average
Max
Min

GM-CSF
0.672
0.404
0.245
0.674
1.151
2.535
0.510
0.885
2.535
0.245

IL-12/23 p40
0.262
0.413
1.546
2.777
0.776
1.648
1.381
0.941
1.218
2.777
0.262

IL-15
0.039
0.049
0.080
0.068
0.058
0.062
0.184
0.032
0.071
0.184
0.032

IL-16
6.999
39.756
104.632
104.052
21.625
59.341
127.012
49.768
64.148
127.012
6.999

IL-17A
0.237
0.578
0.339
0.315
0.808
0.110
0.398
0.808
0.110

IL-1α
8.253
35.308
116.409
187.790
30.900
105.885
535.874
49.374
133.724
535.874
8.253

IL-5
0.193
0.135
0.081
0.111
0.040
0.260
0.109
0.133
0.260
0.040

IL-7
0.143
0.061
0.069
0.145
0.094
0.053
0.159
0.103
0.159
0.053

TNF-β
0.057
0.013
0.028
0.033
0.019
0.028
0.035
0.031
0.057
0.013

VEGF
3.177
15.874
8.601
69.314
20.502
36.638
38.039
15.657
25.975
69.314
3.177

* Data in red indicates that the concentration was in detection range

Table 5: Calculated Concentration Means of Cytokine Markers for Dentate Subjects
(DS) (pg/ml)
DS 09
DS 10
DS 11
DS 12
DS 13
DS 14
DS 15
DS 16
Average
Max
Min

GM-CSF
0.726
1.057
1.314
0.167
1.037
0.370
1.893
0.358
0.865
1.893
0.167

IL-12/23 p40
1.402
2.658
1.211
0.590
4.075
1.334
6.302
0.886
2.307
6.302
0.590

IL-15
0.085
0.118
0.187
0.024
0.301
0.102
0.687
0.063
0.196
0.687
0.024

IL-16
60.781
79.535
122.273
40.028
471.159
43.593
1077.091
60.283
244.343
1077.091
40.028

IL-17A
0.542
0.203
0.236
8.860
0.494
4.071
0.325
2.104
8.860
0.203

IL-1α
86.750
290.141
219.027
119.329
1074.174
204.372
2121.859
80.022
524.459
2121.859
80.022

* Data in red indicates that the concentration was in detection range
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IL-5
0.071
0.063
0.165
0.176
0.416
0.196
0.383
0.162
0.204
0.416
0.063

IL-7
0.106
0.113
0.172
0.065
0.193
0.092
0.339
0.102
0.148
0.339
0.065

TNF-β
0.008
0.016
0.029
0.098
0.051
0.113
0.052
0.052
0.113
0.008

VEGF
16.295
48.038
64.624
16.368
128.639
35.907
163.842
40.929
64.330
163.842
16.295

Table 6: ANOVA of Calculated Concentration Means of Cytokine Markers
Total
Marker
ES DS
Observation
Mean of Response
F Ratio
GM-CSF
7
8
15
0.874292
0.0064
IL-12/23 p40 8
8
16
1.762653
4.4894
IL-15
8
8
16
0.13358
5.4016
IL-16
8
8
16
154.2455
4.1029
IL-17A
6
7
13
1.316736
3.468
IL-1α
8
8
16
329.0917
4.7382
IL-5
7
8
15
0.170769
3.4843
IL-7
7
8
15
0.12714
3.1164
TNF-β
7
7
14
0.041494
4.0762
VEGF
8
8
16
45.15263
7.5234
a
Represents significant differences at the P <0.05 interval (JMP/Pro
Ver12, SAS Inst. Inc., Cary, NC).

P Values
0.936765696
0.042497414 a
0.027077091 a
0.051785708
0.074854568
0.037501293 a
0.072459589
0.088411078
0.053914874
0.010174254 a

Figure 2a. IL-12/23p40 Calculated Concentration Mean Plot (MSD Discovery
Workbench 4.0)
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Figure 2b. Statistical Plot for Calculated Concentration Mean of IL-12/23p40

Figure 3a. IL-15 Calculated Concentration Mean Plot (MSD Discovery Workbench
4.0)
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Figure 3b. Statistical Plot for Calculated Concentration Mean of IL-15

Figure 4a. IL-1α Calculated Concentration Mean Plot (MSD Discovery
Workbench 4.0)
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Figure 4b. Statistical Plot for Calculated Concentration Mean of IL-1α

Figure 5a. VEGF Calculated Concentration Mean Plot (MSD Discovery
Workbench 4.0)

Figure 5b. Statistical Plot for Calculated Concentration Mean of VEGF
36
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Chapter V
DISCUSSION
This current study is a pilot study to determine if MSD analysis is sensitive
enough to determine the presence of significant differences between select cytokines in
the peri-implant crevicular fluid of dentate versus edentulous patients that are restored
with implants. The null hypothesis, that no significant differences in proinflammatory
markers and cytokine markers in the peri-implant crevicular fluid of healthy implants
when comparing implants in edentulous patients and implants in dentate patients, is
rejected.
A total of twenty inflammatory marker levels were tested using MSD Mesoscale
ELISA technology. These markers were divided into two groups – proinflammatory
markers, including IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and,
TNF-α, and cytokines, including GM-CSF, IL-1α, IL-5, IL-7, IL-12/23 p40, IL-15, IL-16,
IL-17A, TNF-β, and, VEGF. These inflammatory markers were divided into groups of
ten due to the limitation of the plates to hold 10 antibodies per well; thus, in order to
incorporate twenty markers, two different 96 well, multi-spot plates were used. These
cytokines were divided according to their cross-reactivity of the antibodies present on the
plate. Out of the twenty markers, five of the levels in peri-implant crevicular fluid were
significantly different between healthy edentulous patients and healthy dentate patients.
Four of the five that were significantly different were in the cytokine group, which
included IL-12/23 p40, IL-15, IL-1α, and VEGF, and one out of the five was in the
proinflammatory group, which included IL-10.
Studies have shown that there are strong correlations between microflora of teeth
and dental implants 2,68-72. It has also been shown that there is a strong correlation
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between the microflora that exists in the biofilms and the cytokine expression that is
present 2,80,81. With these facts in mind, it raises the question whether or not fully
edentulous patients restored with implants will have a significantly different
inflammatory marker expression than implants that are surrounded by natural dentition.
De Waal et al

73

showed that there are higher pathogen-causing bacteria around partially

dentate patients when compared to edentulous patients. Although previous studies have
not investigated comparisons in the cytokine content in PICF between partially and fully
edentulous patients, a hypothesis can be drawn stating that implants in partially dentate
patients will have higher inflammatory responses.

In this study, all inflammatory

marker concentration totals were greater, in pg/ml, in the DS group than the ES group,
except IL-4 and GM-CSF, which were essentially the same. Although all were not
significantly different, the trend towards greater concentrations of inflammatory markers
in dentate patients should be considered. These findings are supported by the literature
when stating that crevicular fluid substituents of natural dentition have a heavy influence
on peri-implant crevicular fluid and will have increased quantities due to the ability to
colonize on hard tissues73,74,77-79.
When interpreting the data for statistical significance, no data was eliminated
even if it was not determined to be within detection range. Due to this study being a pilot
study, all information was considered useful in predicting whether or not significant
enough data presented itself to warrant future studies. Although there is a considerable
amount of data that is considered negligible by the MSD instrument, these small
quantities still make statement concerning that particular cytokines role in PICF. This
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study was used to determine if MSD Mesoscale technology could be used for dental
analysis of PICF measurements.
Due to this study being a pilot study, the small quantity of subjects makes it
difficult to extrapolate the results to apply to a larger population. There are no
correlations that were noted between the five cytokines to be significantly higher in
dentate patients than in edentulous patients. They did not appear to be produced by the
same cell, nor do they elicit similar responses.
Interleukin 12 plays a very important role in inflammation, more specifically,
periodontal diseases. Although all subjects in this study were deemed healthy
individuals, it could be indicative of early signs of bone loss. There is controversy in the
literature about whether or not IL-12 is elevated in peri-implant diseases. Orozco et al84
found that there was no difference in IL-12 levels in inflamed states as compared to
healthy levels84; meanwhile, Tsai et al44 determined that there were higher levels in
diseased states. Future studies should be aimed to clarify the conflicting results from the
previous studies mentioned.
Interleukin 10 has been reported as only found in the GCF of patients with periimplantitis. 36 IL-10 was found in decreased levels in areas that tested positive to having
bleeding on probing 85. Yamazaki et al 86 supported this by suggesting that IL-10 levels
might be critical in immune regulation, controlling the balanace between innate
inflammatory and acquired humoral responses 87. This could support the findings of this
study showing that IL-10 is elevated in patients that are dentate and restored with
implants because even in healthy states, the body’s immune system is fighting off
pathogenic bacteria to a higher extent than edentulous patients due to the influence of
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hard-tissue pathogens. Due to the influence of neighboring microflora, the PICF may
have a much more active immune mediators, rather than in patients where neighboring
microflora from the dentition isn’t creating the same immune reponse. Varying papers
have shown that although IL-10 can be a determinant of inflammation36, it also acts as a
constant regulator of the immune system whether healthy or diseased states are
present87,88.
Vascular endothelial growth factor (VEGF) was shown to be higher in dentate
patients than in edentulous patients restored with implants in this study. VEGF has
demonstrated to be crucial in allowing inflammatory markers to reach a desired site.
Nogueira-Filho82 displayed that lower levels of VEGF have been indicative of healthy
gingival tissue. 82 Booth et al38 suggested that levels could be increased in patients with
weakened healing ability, such as in elderly patients, hence systemic factors and overall
immune system efficiency could have influenced a higher value. Due to lack of
collection of demographic, Booth et al can not be supported in this paper. This fact
supports the theory that although an implant may be clinically healthy, there may still be
inflammation present 9,41.
Interleukin 1 has been closely associated with bone loss in periodontitis 50,51.
Although closely related, IL-1β has been shown to be involved with more destruction,
while Sakai et al 11 found that IL-1alpha along with TNF-α did not have any differences
between healthy and diseased states. IL-1α may have elevated levels due to depth of
pocket31 and was reported as a direct correlation between pocket depth and levels of IL1α.
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Interleukin-15 (IL-15) is produced by mononuclear cells and NK cells. They
stimulate activated B, T and NK cells and chemotaxis. Interleukin 15 has been shown to
be high in inflammatory diseases, such as rheumatoid arthritis 90. Buduneli et al 91 stated
that IL-15 may play a pivotal role in regulation of the leukocyte infiltrate. Due to its
higher levels in the dentate patient, it could support that there is a constant regulation of
immunity components is at a higher level due to presence of hard tissue pathogens
existence in the PICF adjacent to teeth 90.
The statistical differences in this study must be interpreted with caution. The
results of this study are limited by its sample size. Since healthy sulci can have
inflammatory markers, the constituents in the sulci are not just mere predictors of
inflammation or bone loss but a combination of oral pathogens and the functional efforts
of the patients’ systemic immune system as a whole 44,62. If a larger sample size is used,
greater standardization cytokine levels that are present in a healthy individuals despite
age, race, current medications, or pre-existing consitions. This leads to another
limitation which is the lack of demographics collected. Although all patients were
considered healthy, the patients could have had other pre-existing conditions that may
have had an effect on the immune system in a minor but influencial way.
Peri-implant inflammation may be affected by local factors other than bacterial
biofilms, such as implant system and location of the micro-gap10,82. In a future study, the
implant manufacturers should be recorded and standardized to minimize any variables
that could affect the results.
In addition, a limitation of this study could be the dilution of the sample in the TE
Buffer. All samples were placed directly into 1-ml of TE buffer, but only 0.4ml of
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solution was needed to run the appropriate samples. If less of the TE buffer was present
in the vials, there is a possibility to have a more concentrated sample solution. The
maufacturer recommended 1.0ml of TE buffer.
To the authors’ knowledge, there has not been a study that evaluates the cytokines
in the PICF of dentate patients restored with implants and edentulous patients restored
with implants. This study showed that there are significant differences between
edentulous and dentate cytokines. Further studies should perform this same study using a
larger population. It would also be interesting to see if there are differences in the
cytokines in PICF of dentate and edentulous patients in peri-implant disease states.
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Chapter VI:
SUMMARY
A total of twenty inflammatory marker levels were tested using MSD Mesoscale
ELISA technology, including IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL10, IL-12p70, IL-12/23 p40, IL-13, IL-15, IL-16, IL-17A, TNF-α, TNF-β, GM-CSF, and,
VEGF. Out of the twenty markers, five of the levels in peri-implant crevicular fluid
were significantly different between healthy edentulous patients and healthy dentate
patients. Four of the five that were significantly different were in the cytokine group,
which included IL-12/23 p40, IL-15, IL-1α, and VEGF, and one out of the five was in the
proinflammatory group, which included IL-10. The statistical differences in this study
must be interpreted with caution. The results of this study are limited by its sample size.
Since healthy sulci can have inflammatory markers, the constituents in the sulci are not
just mere predictors of inflammation or bone loss but a combination of oral pathogens
and the functional efforts of the patients’ systemic immune system as a whole 44,62.

CONCLUSIONS
1) There is a statistically significant difference between certain cytokines in PICF of
dentate subjects compared to edentulous subjects.
2) There is a tendency towards higher levels of cytokines/inflammatory markers in
PICF of implants in dentate patients compared to edentulous patients
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